alitretinoin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Retinoid receptor.
- Target
- Retinoid receptor
- Mechanism
- Retinoid receptor agonist
pharma · Carcinoma, Non-small-cell Lung · Type 2 Diabetes Mellitus · LGND
LIGAND PHARMACEUTICALS
LIGAND PHARMACEUTICALS INC
LIGAND PHARMACEUTICALS drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US HQ
1987 Founded
130 Employees
Public company Type
LGND · NYSE Ticker
Company details
- Status
- Public
- HQ
- 555 Heritage Dr, Suite 200, Jupiter, Florida 33458, US
- Founded
- 1987
- Employees
- 130
- Programs
- 34
- Drugs
- 25
- Patents
- 133
LIGAND PHARMACEUTICALS pipeline
Portfolio lens on 25 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
LIGAND PHARMACEUTICALS drug portfolio — 25 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
bexarotene
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Retinoid X receptor.
- Target
- Retinoid X receptor
- Mechanism
- Retinoid X receptor agonist
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
US regulatory status: approved. Molecular target: Elongation factor 2.
- Target
- Elongation factor 2
- Mechanism
- Interleukin-2 receptor binding agent
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in LIGAND PHARMACEUTICALS's portfolio.
-
erlotinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in LIGAND PHARMACEUTICALS's portfolio. Mechanism: Epidermal growth factor receptor erbB1 inhibitor.
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
Development asset linked to LIGAND PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
irbesartan
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
lasofoxifene
Genito-urinary system and sex hormones (G03)Genito-urinary system and sex hormones (G03) compound in LIGAND PHARMACEUTICALS's portfolio. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor modulator
-
Development asset linked to LIGAND PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to LIGAND PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to LIGAND PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to LIGAND PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Osmotic laxative.
- Mechanism
- Osmotic laxative
-
US regulatory status: approved. Molecular target: Angiotensin-converting enzyme.
- Target
- Angiotensin-converting enzyme
- Mechanism
- Angiotensin-converting enzyme inhibitor
-
Development asset linked to LIGAND PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to LIGAND PHARMACEUTICALS in public FDA and regional records.
-
Development asset linked to LIGAND PHARMACEUTICALS in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist